[go: up one dir, main page]

WO2002080914A3 - VERWENDUNG VON SUBSTITUIERTEN IMIDAZO[1,2-a]-PYRIDINVERBINDUNGEN ALS ARZNEIMITTEL - Google Patents

VERWENDUNG VON SUBSTITUIERTEN IMIDAZO[1,2-a]-PYRIDINVERBINDUNGEN ALS ARZNEIMITTEL Download PDF

Info

Publication number
WO2002080914A3
WO2002080914A3 PCT/EP2002/003795 EP0203795W WO02080914A3 WO 2002080914 A3 WO2002080914 A3 WO 2002080914A3 EP 0203795 W EP0203795 W EP 0203795W WO 02080914 A3 WO02080914 A3 WO 02080914A3
Authority
WO
WIPO (PCT)
Prior art keywords
medicaments
pyridine compounds
substituted imidazo
substituted
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/003795
Other languages
English (en)
French (fr)
Other versions
WO2002080914A2 (de
Inventor
Corinna Maul
Hagen-Heinrich Hennies
Bernd Sundermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Priority to JP2002578953A priority Critical patent/JP2004529141A/ja
Priority to MXPA03008965A priority patent/MXPA03008965A/es
Priority to CA002442996A priority patent/CA2442996A1/en
Priority to HU0401302A priority patent/HUP0401302A2/hu
Priority to EP02727529A priority patent/EP1372647A2/de
Publication of WO2002080914A2 publication Critical patent/WO2002080914A2/de
Publication of WO2002080914A3 publication Critical patent/WO2002080914A3/de
Priority to US10/678,645 priority patent/US20040142961A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Die vorliegende Erfindung betrifft die Verwendung substituierter Imidazo[1,2-a]-pyridinverbindungen sowie ihrer physiologisch verträgliche Salze als Inhibitoren für die Stickstoffmonoxid-Synthase und zur Herstellung von Arzneimitteln.
PCT/EP2002/003795 2001-04-05 2002-04-05 VERWENDUNG VON SUBSTITUIERTEN IMIDAZO[1,2-a]-PYRIDINVERBINDUNGEN ALS ARZNEIMITTEL Ceased WO2002080914A2 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2002578953A JP2004529141A (ja) 2001-04-05 2002-04-05 置換されたイミダゾ［１，２−ａ］ピリジン化合物を医薬として使用する方法
MXPA03008965A MXPA03008965A (es) 2001-04-05 2002-04-05 Uso de compuestos de imidazo [1,2-a]-piridinas sustituidas como medicamentos.
CA002442996A CA2442996A1 (en) 2001-04-05 2002-04-05 Use of substituted imidazo[1,2-a]-pyridine compounds as medicaments
HU0401302A HUP0401302A2 (hu) 2001-04-05 2002-04-05 Helyettesített imidazo[1,2-a]piridin-vegyületek felhasználása gyógyszerként
EP02727529A EP1372647A2 (de) 2001-04-05 2002-04-05 VERWENDUNG VON SUBSTITUIERTEN IMIDAZO 1,2-a]-PYRIDINVERBINDUNGEN ALS ARZNEIMITTEL
US10/678,645 US20040142961A1 (en) 2001-04-05 2003-10-03 Utilization of substituted imidazo[1,2-a]-pyridine compounds in pharmaceutical formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10117183A DE10117183A1 (de) 2001-04-05 2001-04-05 Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel
DE10117183.8 2001-04-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/678,645 Continuation US20040142961A1 (en) 2001-04-05 2003-10-03 Utilization of substituted imidazo[1,2-a]-pyridine compounds in pharmaceutical formulations

Publications (2)

Publication Number Publication Date
WO2002080914A2 WO2002080914A2 (de) 2002-10-17
WO2002080914A3 true WO2002080914A3 (de) 2003-01-03

Family

ID=7680630

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/003795 Ceased WO2002080914A2 (de) 2001-04-05 2002-04-05 VERWENDUNG VON SUBSTITUIERTEN IMIDAZO[1,2-a]-PYRIDINVERBINDUNGEN ALS ARZNEIMITTEL

Country Status (9)

Country Link
US (1) US20040142961A1 (de)
EP (1) EP1372647A2 (de)
JP (1) JP2004529141A (de)
CA (1) CA2442996A1 (de)
DE (1) DE10117183A1 (de)
HU (1) HUP0401302A2 (de)
MX (1) MXPA03008965A (de)
PL (1) PL366858A1 (de)
WO (1) WO2002080914A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10247271A1 (de) * 2002-10-10 2004-08-26 Grünenthal GmbH Substituierte C-Imidazo[1,2-a]pyridin-3-yle
HUE047422T2 (hu) 2005-12-23 2020-04-28 Ariad Pharma Inc Biciklusos heteroaril vegyületek
WO2007140511A1 (en) * 2006-06-02 2007-12-13 Cbb International Pty Ltd A monitoring system
US8236841B2 (en) 2006-09-13 2012-08-07 Kyowa Hakko Kirin Co., Ltd. Fused heterocycle derivative
JP5442449B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
HRP20150642T1 (hr) 2006-12-22 2015-08-14 Astex Therapeutics Limited BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
JP5456681B2 (ja) * 2007-10-17 2014-04-02 ノバルティス アーゲー ＡＬＫ阻害剤として有用なイミダゾ［１，２−ａ］ピリジン誘導体
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
TW201018682A (en) * 2008-09-25 2010-05-16 Kyorin Seiyaku Kk Heterocyclic biaryl derivative, and pde inhibitor comprising same as active ingredient
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
US9173887B2 (en) 2010-12-22 2015-11-03 Abbvie Inc. Hepatitis C inhibitors and uses thereof
EP2881394B1 (de) 2012-07-31 2018-03-21 Kyowa Hakko Kirin Co., Ltd. Kondensierte heterocyclische ringverbindung
EP4306522A4 (de) * 2021-03-11 2025-05-21 Zhejiang University Heterocyclische verbindung mit kondensiertem ring und anwendung davon sowie pharmazeutische zusammensetzung damit und anwendung davon
CN115073449A (zh) * 2021-03-11 2022-09-20 浙江大学 稠环杂环化合物及应用、含有其的药物组合物及应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4382938A (en) * 1980-10-22 1983-05-10 Synthelabo Imidazo[1,2-a] pyridine derivatives and their application as pharmaceuticals
WO1996025414A1 (en) * 1995-02-15 1996-08-22 Pharmacia & Upjohn Company Imidazo[1,2-a]pyridines for the treatment of cns and cardiac diseases
US5614531A (en) * 1994-02-19 1997-03-25 Merck Patent Gesellschaft Mit Beschrankter Haftung Adhesion receptor antagonists
US5891891A (en) * 1995-04-07 1999-04-06 Clarendon-Trading & Investimentos Lda Use of imidazo 1, 2-A! pyridine-3-acetamide derivatives for the therapeutic treatment of neuropsychiatric syndromes associated with disfunction of the neural circuits of the basal ganglia
US6013654A (en) * 1997-08-14 2000-01-11 Pharmacia & Upjohn Company Imidazo[1,2-A]pyridines for the treatment of CNS and cardiac diseases
WO2001027109A2 (de) * 1999-10-08 2001-04-19 Grünenthal GmbH Tert.-butyl-(7-methyl-imidazo[1,2-a]pyridin-3-yl)-amin-derivate
DE10050663A1 (de) * 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3269604D1 (en) * 1981-06-26 1986-04-10 Schering Corp Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them
US4791117A (en) * 1986-09-22 1988-12-13 Ortho Pharmaceutical Corporation 2- or 3-aryl substituted imidazo[1,2-a]pyridines and their use as calcium channel blockers
NZ221996A (en) * 1986-10-07 1989-08-29 Yamanouchi Pharma Co Ltd Imidazo-pyridine derivatives and pharmaceutical compositions
AU6355190A (en) * 1989-06-13 1991-01-17 Smithkline Beecham Corporation Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages
US5912248A (en) * 1995-11-16 1999-06-15 Eli Lilly And Company Excitatory amino acid receptor antagonists
DE19602855A1 (de) * 1996-01-26 1997-07-31 Byk Gulden Lomberg Chem Fab Neue 3-Methylimidazopyridine

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4382938A (en) * 1980-10-22 1983-05-10 Synthelabo Imidazo[1,2-a] pyridine derivatives and their application as pharmaceuticals
US5614531A (en) * 1994-02-19 1997-03-25 Merck Patent Gesellschaft Mit Beschrankter Haftung Adhesion receptor antagonists
WO1996025414A1 (en) * 1995-02-15 1996-08-22 Pharmacia & Upjohn Company Imidazo[1,2-a]pyridines for the treatment of cns and cardiac diseases
US5912246A (en) * 1995-02-15 1999-06-15 Pharmacia & Upjohn Company Imidazo 1,2-a!pyridines for the treatment of CNS and cardiac diseases
US5891891A (en) * 1995-04-07 1999-04-06 Clarendon-Trading & Investimentos Lda Use of imidazo 1, 2-A! pyridine-3-acetamide derivatives for the therapeutic treatment of neuropsychiatric syndromes associated with disfunction of the neural circuits of the basal ganglia
US6013654A (en) * 1997-08-14 2000-01-11 Pharmacia & Upjohn Company Imidazo[1,2-A]pyridines for the treatment of CNS and cardiac diseases
WO2001027109A2 (de) * 1999-10-08 2001-04-19 Grünenthal GmbH Tert.-butyl-(7-methyl-imidazo[1,2-a]pyridin-3-yl)-amin-derivate
DE10050663A1 (de) * 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung

Also Published As

Publication number Publication date
PL366858A1 (en) 2005-02-07
JP2004529141A (ja) 2004-09-24
DE10117183A1 (de) 2002-10-10
CA2442996A1 (en) 2002-10-17
WO2002080914A2 (de) 2002-10-17
US20040142961A1 (en) 2004-07-22
HUP0401302A2 (hu) 2004-12-28
MXPA03008965A (es) 2004-02-12
EP1372647A2 (de) 2004-01-02

Similar Documents

Publication Publication Date Title
WO2002080914A3 (de) VERWENDUNG VON SUBSTITUIERTEN IMIDAZO[1,2-a]-PYRIDINVERBINDUNGEN ALS ARZNEIMITTEL
ZA200605901B (en) Pyrazolo [3,4-B] pyridine compounds, and their use as phosphodiesterase inhibitors
IL191960A (en) History of imidazo [5,1– a] pyridine and pharmaceutical preparations containing them
AU2001289751A1 (en) Selective pde 2 inhibitors, used as medicaments for improving cognition
WO2003013541A8 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
WO2005037198A3 (en) Preparation of 1,7-disubstituted azabenzimidazoles as kinase inhibitors
WO2001047928A3 (de) Imidazo 1,3,5 triazinone und ihre verwendung
IL175487A (en) Pyrazole derivatives, a process for their preparation and use in the manufacture of drugs and drugs for inhibiting trk activity
WO2005049581A8 (en) Pyridazin-3 (2h) -one derivatives and their use as pde4 inhibitors
HUP0600068A3 (en) Pyrido[2,1-a]isoquinoline derivatives as dpp-iv inhibitors, process for their preparation and pharmaceutical compositions thereof
PL369531A1 (en) 1,8-naphthyridine derivatives as antidiabetics
HUP0303350A3 (en) Use of substituted imidazo[1,2-a]pyridine-, imidazo[1,2-a]pyrimidine and imidazo[1,2-a]pyrazine-3-yl-amine derivatives for producing nos-inhibiting pharmaceutical compositions
WO2007025540A3 (de) Substituierte imidazo[1,2b]pyridazine als kinase-inhibitoren, deren herstellung und verwendung als arzneimittel
EP1670466A4 (de) Zubereitung von 1,6,7-trisubstituierten azabenzimidazolen als kinasehemmer
HUP0401292A3 (en) Pyrazolo[1,5-a]pyridines, pharmaceutical compositions containing the same and process for preparation thereof
IL170680A0 (en) 8 - SUBSTITUTED - 6,7,8,9 -TETRAHYDROPYRIMIDO [1,2-a] PYRIMIDIN - 4 - ONE DERIVATIVES
PT1674456E (pt) Utilização de 2-fluoro-3-cetoésteres para preparar 3-fluoro- 6,7,8,9-tetra-hidro-4-h-pirimido[1,2-a]pirimidin-4-onas
AU2003255323A8 (en) Imidazo`1,2-a pyridines
HUP0003118A3 (en) Use of 2,7-substituted octahydro-1h-pyrido [1,2-a]pyrazine derivatives for production of pharmaceutical compositions
IL172369A (en) History of 2-Transformed Phenyl-5, 7-Dialkyl-3, 7-Dihydropyrrolo- [3,2-d] Pyrimidin-4-Ven, process for their preparation, and pharmaceutical preparations containing them
WO2002080911A3 (de) Verwendung substituierter imidazo[1,2-a]-pyridin-3-yl-amid- und imidazo[1,2-a]-pyridin-3-yl-aminverbindungen als arzneimittel zur behandlung von neurodegenerativen erkrankungen
HUP0600084A2 (en) Pharmaceutical compositions containing ascorbic acid derivatives, methods of production of the active ingredient
DK1275647T3 (da) Octahydro-1H-pyrido[1,2-a]pyrazinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
AU2003224482A8 (en) Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
CA2445189A1 (en) Carboline derivatives as pdev inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/008965

Country of ref document: MX

Ref document number: 528595

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 10678645

Country of ref document: US

Ref document number: 2002578953

Country of ref document: JP

Ref document number: 2442996

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002727529

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002257753

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2002727529

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002727529

Country of ref document: EP